Stockreport

Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF SALT LAKE CITY, May 30, 2019 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncolo [Read more]